Cover Image

Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study

Conversion from calcineurin inhibitor (CNI) therapy to everolimus within 6 months after kidney transplantation improves long-term graft function but can increase the risk of mild biopsy-proven acute cellular rejection (BPAR). We performed a post-hoc analysis of histological data from a randomized tr...

Full description

Saved in:
Bibliographic Details
Main Authors: Eisenberger, Ute (Author) , Sommerer, Claudia (Author)
Format: Article (Journal)
Language:English
Published: 28 June 2018
In: BMC nephrology
Year: 2018, Volume: 19, Pages: 1-8
ISSN:1471-2369
DOI:10.1186/s12882-018-0950-1
Online Access:Verlag, Volltext: https://doi.org/10.1186/s12882-018-0950-1
Verlag, Volltext: https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-018-0950-1
Get full text
Author Notes:Ute Eisenberger, Klemens Budde, Frank Lehner, Claudia Sommerer, Petra Reinke, Oliver Witzke, Rudolf P. Wüthrich, Rolf Stahl, Katharina Heller, Barbara Suwelack, Anja Mühlfeld, Ingeborg A. Hauser, Silvio Nadalin, Martina Porstner, Wolfgang Arns
Description
Summary:Conversion from calcineurin inhibitor (CNI) therapy to everolimus within 6 months after kidney transplantation improves long-term graft function but can increase the risk of mild biopsy-proven acute cellular rejection (BPAR). We performed a post-hoc analysis of histological data from a randomized trial in order to further analyze histologic information obtained from indication and protocol biopsies up to 5 years after transplantation.
Item Description:Gesehen am 13.08.2019
Physical Description:Online Resource
ISSN:1471-2369
DOI:10.1186/s12882-018-0950-1

Similar Items